Outcomes of immune checkpoint inhibitors for postoperative recurrence of non-small cell lung cancer.
暂无分享,去创建一个
H. Date | T. Menju | Y. Yutaka | M. Hamaji | Y. Sakamori | H. Ozasa | Itsuki Yuasa | H. Yoshida | Toyohiro Hirai
[1] T. Yokoi,et al. Osimertinib as first-line treatment for advanced epidermal growth factor receptor mutation-positive non-small-cell lung cancer in a real-world setting (OSI-FACT). , 2021, European journal of cancer.
[2] A. Yoshizawa,et al. Epidermal growth factor receptor (EGFR)—tyrosine kinase inhibitors as a first-line treatment for postoperative recurrent and EGFR-mutated non-small-cell lung cancer , 2021, Interactive cardiovascular and thoracic surgery.
[3] Joe Y. Chang,et al. NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 2.2021. , 2021, Journal of the National Comprehensive Cancer Network : JNCCN.
[4] D. Ettinger,et al. Multisystem Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors for Treatment of Non-Small Cell Lung Cancer. , 2020, JAMA oncology.
[5] Y. Ishikawa,et al. Characteristics of surgically resected non‐small cell lung cancer patients with post‐recurrence cure , 2020, Thoracic cancer.
[6] Y. Hosomi,et al. Safety and efficacy of pembrolizumab monotherapy in elderly patients with PD-L1-positive advanced non-small-cell lung cancer: Pooled analysis from the KEYNOTE-010, KEYNOTE-024, and KEYNOTE-042 studies. , 2019, Lung cancer.
[7] T. Yamanaka,et al. The Japanese Lung Cancer Society Guideline for non-small cell lung cancer, stage IV , 2019, International Journal of Clinical Oncology.
[8] P. V. Van Schil,et al. Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.
[9] V. Gebski,et al. Clinical and Molecular Characteristics Associated With Survival Among Patients Treated With Checkpoint Inhibitors for Advanced Non–Small Cell Lung Carcinoma: A Systematic Review and Meta-analysis , 2017, JAMA oncology.
[10] M. Tsuboi,et al. Long‐term survival outcome after postoperative recurrence of non‐small‐cell lung cancer: who is ‘cured’ from postoperative recurrence? , 2017, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.
[11] M. Tsuboi,et al. Postoperative oligo-recurrence of non-small-cell lung cancer: clinical features and survival†. , 2016, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.
[12] M. Sonobe,et al. Gefitinib treatment in patients with postoperative recurrent non-small-cell lung cancer harboring epidermal growth factor receptor gene mutations , 2015, International Journal of Clinical Oncology.
[13] C. Kang,et al. Prognostic and predictive role of epidermal growth factor receptor mutation in recurrent pulmonary adenocarcinoma after curative resection. , 2015, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.
[14] PhD Makoto Sonobe MD,et al. Identification of Subsets of Patients with Favorable Prognosis After Recurrence in Completely Resected Non-Small Cell Lung Cancer , 2014, Annals of Surgical Oncology.
[15] P. Pairolero,et al. Survival after recurrent nonsmall-cell lung cancer after complete pulmonary resection. , 2007, The Annals of thoracic surgery.
[16] A. Bogers,et al. Charlson comorbidity index as a predictor of long-term outcome after surgery for nonsmall cell lung cancer. , 2005, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.